Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2011, Article ID 656013, 7 pages
http://dx.doi.org/10.1155/2011/656013
Review Article

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma

Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA

Received 12 July 2010; Accepted 27 February 2011

Academic Editor: Jorge Enrique Romaguera

Copyright © 2011 Bhanu Vakkalanka and Brian K. Link. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. E. Caporaso, L. R. Goldin, W. F. Anderson, and O. Landgren, “Current insight on trends, causes, and mechanisms of Hodgkin's lymphoma,” Cancer Journal, vol. 15, no. 2, pp. 117–123, 2009. View at Publisher · View at Google Scholar · View at PubMed
  2. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” Ca-A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005. View at Google Scholar
  3. N. L. Harris, E. S. Jaffe, H. Stein et al., “A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group,” Blood, vol. 84, no. 5, pp. 1361–1392, 1994. View at Google Scholar
  4. T. A. Lister, D. Crowther, S. B. Sutcliffe et al., “Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: cotswolds meeting,” Journal of Clinical Oncology, vol. 7, no. 11, pp. 1630–1636, 1989. View at Google Scholar
  5. C. Fermé, H. Eghbali, J. H. Meerwaldt et al., “Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease,” New England Journal of Medicine, vol. 357, no. 19, pp. 1916–1927, 2007. View at Publisher · View at Google Scholar · View at PubMed
  6. C. Herbst, F. A. Rehan, C. Brillant et al., “Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review,” Haematologica, vol. 95, no. 3, pp. 494–500, 2010. View at Publisher · View at Google Scholar · View at PubMed
  7. A. Engert, J. Franklin, H. T. Eich et al., “Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial,” Journal of Clinical Oncology, vol. 25, no. 23, pp. 3495–3502, 2007. View at Publisher · View at Google Scholar · View at PubMed
  8. B. Klimm and A. Engert, “Combined modality treatment of Hodgkin's lymphoma,” Cancer Journal, vol. 15, no. 2, pp. 143–149, 2009. View at Publisher · View at Google Scholar · View at PubMed
  9. J. Kuruvilla, “Standard therapy of advanced Hodgkin lymphoma,” Hematology, pp. 497–506, 2009. View at Google Scholar
  10. G. P. Canellos, J. R. Anderson, K. J. Propert et al., “Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD,” New England Journal of Medicine, vol. 327, no. 21, pp. 1478–1484, 1992. View at Google Scholar
  11. S. J. Horning, R. T. Hoppe, S. Breslin, N. L. Bartlett, B. William Brown, and S. A. Rosenberg, “Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial,” Journal of Clinical Oncology, vol. 20, no. 3, pp. 630–637, 2002. View at Publisher · View at Google Scholar
  12. V. Diehl, J. Franklin, M. Pfreundschuh et al., “Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease,” New England Journal of Medicine, vol. 348, no. 24, pp. 2386–2395, 2003. View at Publisher · View at Google Scholar · View at PubMed
  13. D. B. Duggan, G. R. Petroni, J. L. Johnson et al., “Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial,” Journal of Clinical Oncology, vol. 21, no. 4, pp. 607–614, 2003. View at Publisher · View at Google Scholar
  14. P. G. Gobbi, A. Levis, T. Chisesi et al., “ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi,” Journal of Clinical Oncology, vol. 23, no. 36, pp. 9198–9207, 2005. View at Publisher · View at Google Scholar · View at PubMed
  15. A. Thomas, R. D. Gingrich, B. J. Smith et al., “18-fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports,” Leukemia and Lymphoma, vol. 51, no. 3, pp. 439–446, 2010. View at Publisher · View at Google Scholar · View at PubMed
  16. P. W. M. Johnson, J. A. Radford, M. H. Cullen et al., “Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519),” Journal of Clinical Oncology, vol. 23, no. 36, pp. 9208–9218, 2005. View at Publisher · View at Google Scholar · View at PubMed
  17. M. Federico, S. Luminari, E. Iannitto et al., “ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial,” Journal of Clinical Oncology, vol. 27, no. 5, pp. 805–811, 2009. View at Publisher · View at Google Scholar · View at PubMed
  18. P. W. M. Johnson, A. Horwich, A. Jack et al., “Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244,” in Proceedings of the 50th ASH Annual Meeting Abstracts, vol. 112, p. 370, 2008.
  19. A. Engert, P. Schiller, A. Josting et al., “Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's lymphoma study group,” Journal of Clinical Oncology, vol. 21, no. 19, pp. 3601–3608, 2003. View at Publisher · View at Google Scholar · View at PubMed
  20. A. R. Domínguez, A. Márquez, J. Gumá et al., “Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study,” Annals of Oncology, vol. 15, no. 12, pp. 1798–1804, 2004. View at Publisher · View at Google Scholar · View at PubMed
  21. D. J. Straus, C. S. Portlock, J. Qin et al., “Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease,” Blood, vol. 104, no. 12, pp. 3483–3489, 2004. View at Publisher · View at Google Scholar · View at PubMed
  22. G. P. Bodey, M. Buckley, Y. S. Sathe, and E. J. Freireich, “Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia,” Annals of Internal Medicine, vol. 64, no. 2, pp. 328–340, 1966. View at Google Scholar
  23. A. Santoro, G. Bonadonna, P. Valagussa et al., “Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy,” Journal of Clinical Oncology, vol. 5, no. 1, pp. 27–37, 1987. View at Google Scholar
  24. P. Carde, F. R. MacKintosh, and S. A. Rosenberg, “A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy,” Journal of Clinical Oncology, vol. 1, no. 2, pp. 146–153, 1983. View at Google Scholar
  25. R. E. N. van Rijswijk, C. Haanen, A. W. Dekker, A. J. de Meijer, and J. Verbeek, “Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease,” Journal of Clinical Oncology, vol. 7, no. 12, pp. 1776–1782, 1989. View at Google Scholar
  26. A. M. Evens, J. Cilley, T. Ortiz et al., “G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis,” British Journal of Haematology, vol. 137, no. 6, pp. 545–552, 2007. View at Publisher · View at Google Scholar · View at PubMed
  27. O. Landgren, C. Algernon, U. Axdorph et al., “Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis,” Haematologica, vol. 88, no. 4, pp. 438–444, 2003. View at Google Scholar
  28. J. H. Goldie and A. J. Coldman, “Quantitative model for multiple levels of drug resistance in clinical tumors,” Cancer Treatment Reports, vol. 67, no. 10, pp. 923–931, 1983. View at Google Scholar
  29. V. T. DeVita Jr., “The evolution of chemotherapy of lymphomas of adults,” Leukemia, vol. 1, no. 6, pp. 467–485, 1987. View at Google Scholar
  30. R. A. Beveridge, J. A. Miller, A. N. Kales et al., “A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression,” Cancer Investigation, vol. 16, no. 6, pp. 366–373, 1998. View at Google Scholar
  31. J. Bohlius, C. Herbst, M. Reiser, G. Schwarzer, and A. Engert, “Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD003189, 2008. View at Google Scholar
  32. V. K. Chand, B. K. Link, J. M. Ritchie, M. Shannon, and J. E. Wooldridge, “Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy,” Leukemia and Lymphoma, vol. 47, no. 4, pp. 657–663, 2006. View at Publisher · View at Google Scholar · View at PubMed
  33. E. Boleti and G. M. Mead, “ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors,” Annals of Oncology, vol. 18, no. 2, pp. 376–380, 2007. View at Publisher · View at Google Scholar · View at PubMed
  34. J. Nangalia, H. Smith, and J. Z. Wimperis, “Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support,” Leukemia and Lymphoma, vol. 49, no. 8, pp. 1530–1536, 2008. View at Publisher · View at Google Scholar · View at PubMed
  35. W. G. Martin, K. M. Ristow, T. M. Habermann, J. P. Colgan, T. E. Witzig, and S. M. Ansell, “Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 23, no. 30, pp. 7614–7620, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. T. J. Smith, J. Khatcheressian, G. H. Lyman et al., “2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline,” Journal of Clinical Oncology, vol. 24, no. 19, pp. 3187–3205, 2006. View at Publisher · View at Google Scholar · View at PubMed
  37. M. S. Aapro, D. A. Cameron, R. Pettengell et al., “EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours,” European Journal of Cancer, vol. 42, no. 15, pp. 2433–2453, 2006. View at Publisher · View at Google Scholar · View at PubMed
  38. G. Bucaneve, A. Micozzi, F. Menichetti et al., “Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia,” New England Journal of Medicine, vol. 353, no. 10, pp. 977–987, 2005. View at Publisher · View at Google Scholar · View at PubMed
  39. M. Cullen, N. Steven, L. Billingham et al., “Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas,” New England Journal of Medicine, vol. 353, no. 10, pp. 988–998, 2005. View at Publisher · View at Google Scholar · View at PubMed
  40. A. Gafter-Gvili, A. Fraser, M. Paul, and L. Leibovici, “Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients,” Annals of Internal Medicine, vol. 142, no. 12, part 1, pp. 979–995, 2005. View at Google Scholar
  41. A. Gafter-Gvili, M. Paul, A. Fraser, and L. Leibovici, “Antibiotic prophylaxis in neutropenic patients,” Israel Medical Association Journal, vol. 9, no. 6, pp. 460–462, 2007. View at Google Scholar
  42. R. J. Biggar, E. S. Jaffe, J. J. Goedert, A. Chaturvedi, R. Pfeiffer, and E. A. Engels, “Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS,” Blood, vol. 108, no. 12, pp. 3786–3791, 2006. View at Publisher · View at Google Scholar · View at PubMed
  43. R. Rubio, “Hodgkin's disease associated with human immunodeficiency virus infection: a clinical study of 46 cases,” Cancer, vol. 73, no. 9, pp. 2400–2407, 1994. View at Google Scholar
  44. U. Tirelli, D. Errante, R. Dolcetti et al., “Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors,” Journal of Clinical Oncology, vol. 13, no. 7, pp. 1758–1767, 1995. View at Google Scholar · View at Scopus
  45. J. Berenguer, P. Miralles, J. M. Ribera et al., “Characteristics and outcome of AIDS-related hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy,” Journal of Acquired Immune Deficiency Syndromes, vol. 47, no. 4, pp. 422–428, 2008. View at Publisher · View at Google Scholar · View at PubMed
  46. B. Xicoy, J. M. Ribera, P. Miralles et al., “Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma,” Haematologica, vol. 92, no. 2, pp. 191–198, 2007. View at Google Scholar · View at Scopus